Welcome to our dedicated page for Journey Medical SEC filings (Ticker: DERM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Journey Medical Corporation (DERM) SEC filings page on Stock Titan provides access to the company’s public regulatory documents as filed with the U.S. Securities and Exchange Commission. Journey Medical is a commercial-stage pharmaceutical company focused on selling and marketing FDA-approved prescription pharmaceutical products for dermatological conditions, with its common stock listed on The Nasdaq Capital Market under the symbol DERM and registered pursuant to Section 12(b) of the Securities Exchange Act of 1934.
Through its SEC filings, investors can review Journey Medical’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe its dermatology-focused business, portfolio of eight branded FDA-approved prescription drugs, risk factors, and financial statements. Current reports on Form 8-K provide updates on material events, including quarterly financial results, amendments to credit agreements, at-the-market equity sales programs, changes to the company’s certificate of incorporation, index inclusion announcements, and disclosures related to the commercialization and pharmacy benefit coverage of Emrosi (DFD-29) for inflammatory lesions of rosacea in adults.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand topics such as Journey Medical’s revenue composition, term loan arrangements, equity issuance programs, governance changes, and other significant disclosures. Real-time updates from the EDGAR system ensure that new 8-Ks, 10-Qs, and 10-Ks are reflected promptly, while access to exhibits and related materials allows for deeper review when needed.
In addition, users can monitor forms that disclose capital markets and corporate actions referenced in Journey Medical’s filings. By combining original SEC documents with AI-generated explanations, this page is intended to make Journey Medical’s regulatory history and ongoing reporting more accessible to investors, analysts, and others researching DERM.
Journey Medical Corporation (DERM) filed a Form 4 reporting that director Miranda Jayne Toledano received an equity award on 25 June 2025.
- Grant: 7,173 restricted stock units (RSUs) under the 2015 Stock Plan at a grant price of $0.
- Vesting: The RSUs will vest in full on 25 June 2026.
- Post-grant ownership: Toledano now beneficially owns 88,618 Journey Medical common shares, including unvested RSUs, all held directly.
No shares were sold or otherwise disposed of, and no derivative securities were involved. The filing, signed by attorney-in-fact Ramsey Alloush on 07 July 2025, represents a routine director compensation event rather than an open-market transaction.
Journey Medical Corp. (DERM) – Form 4 insider transaction
On June 25 2025, Director Dr. Lindsay A. Rosenwald received 7,173 restricted stock units (RSUs) at a cost of $0 under the company’s 2015 Stock Plan. The RSUs will vest in full on June 25 2026.
After this grant, Dr. Rosenwald beneficially owns 161,146 shares directly and 176,470 shares indirectly through a limited-liability company of which she is the managing member—an aggregate of 337,616 common shares. No shares were sold, and no derivative securities were involved.
The filing reflects routine equity compensation intended to align the director’s interests with shareholders. The grant size is modest relative to typical daily trading volume and does not materially affect the company’s share count or control structure.
Journey Medical Corp (DERM) – Form 4 insider filing: Director Michael Cooper Pearce was granted 7,173 restricted stock units (RSUs) on 25 Jun 2025 under the company’s 2015 Stock Plan. The award was issued at no cost and will vest in full on 25 Jun 2026. After the grant, Pearce’s direct beneficial ownership rose to 37,173 shares, which includes previously awarded RSUs that vest over various schedules. No open-market purchases or sales occurred, and there was no cash consideration. The transaction is routine equity compensation intended to align the director’s interests with shareholders, with only immaterial dilution to existing holders.
Journey Medical (NASDAQ:DERM) filed an 8-K detailing the June 24, 2025 annual meeting results and a Fourth Amended & Restated Certificate of Incorporation. Stockholders owning 85.0% of voting power approved three items:
- Election of six directors for one-year terms
- Ratification of KPMG LLP as 2025 auditor (32,468,451 for; 10,433 against)
- Adoption of the amended charter, which now exculpates corporate officers from certain personal liability
Total votes for the charter change were 25,373,988 for and 798,994 against, with 10,387 abstentions and 6,319,771 broker non-votes. The filing is effective upon Delaware acceptance and is furnished as Exhibit 3.1.
FAQ
What is the current stock price of Journey Medical (DERM)?
What is the market cap of Journey Medical (DERM)?
